<DOC>
	<DOC>NCT00296504</DOC>
	<brief_summary>GW433908 (fosamprenavir; FPV)is a pro-drug of amprenavir (APV) which is more water soluble and can be formulated into a tablet with a reduced pill burden (four 700mg tablets of FPV versus sixteen 150mg capsules daily for APV. This study is designed to provide additional information on long term safety and tolerability of FPV containing regimens for those subjects who received FPV in previous GlaxoSmithKline studies.</brief_summary>
	<brief_title>A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects</brief_title>
	<detailed_description>ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Male or nonpregnant/nonlactating females &gt;/=13 years of age (or &gt;/= 18 years of age according to local requirements). Received fosamprenavir through prior participation in APV20001, APV30002, APV30003 or PRO30017 or have participated in APV30001 or other studies as deemed appropriate by the project team. Permanent discontinuation of GW433908 in a previous study due to intolerance. An active CDC Class C Event. Any condition which, in the opinion of the investigator, would preclude a subject from participation.</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>antiretroviral therapy naive subjects</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>HIV-1</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>pro-drug</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>LEXIVA</keyword>
	<keyword>AGENERASE</keyword>
	<keyword>GW433908</keyword>
	<keyword>amprenavir</keyword>
</DOC>